Lucid Capital analyst Dev Prasad initiated coverage of Avalo Therapeutics (AVTX) with a Buy rating and $24 price target The company’s lead asset, AVTX-009, is an anti-IL-1beta monoclonal antibody targeting inflammatory diseases, beginning with hidradenitis suppurativa, the analyst tells investors in a research note. The firm projects adjusted 2042 peak sales of $405M for AVTX-009 in HS alone, with additional upside from its potential application in other inflammatory diseases, such as inflammatory bowel disease. It believes Avalo “represents a compelling opportunity for long-term growth.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AVTX:
- Avalo Therapeutics (AVTX) Is a Potential Hidden Gem with Significant Risk
- Avalo Therapeutics receives $69.4M in proceeds from exercise of warrants
- Avalo Therapeutics reports Q3 EPS ($2.83) vs ($22.83) last year
- Avalo Therapeutics, Inc. (AVTX) Q3 Earnings Cheat Sheet
- Avalo Therapeutics initiated with a Neutral at H.C. Wainwright